Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:SRD5A1-GRK4

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: SRD5A1-GRK4
	FusionPDB ID: 86271
	FusionGDB2.0 ID: 86271
		Hgene	Tgene
	Gene symbol	SRD5A1	GRK4
	Gene ID	6715	2868
	Gene name	steroid 5 alpha-reductase 1	G protein-coupled receptor kinase 4
	Synonyms	S5AR 1	GPRK2L\|GPRK4\|GRK4a\|IT11
	Cytomap	5p15.31	4p16.3
	Type of gene	protein-coding	protein-coding
	Description	3-oxo-5-alpha-steroid 4-dehydrogenase 1SR type 1steroid 5-alpha-reductase type Isteroid-5-alpha-reductase, alpha polypeptide 1 (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 1)	G protein-coupled receptor kinase 4G protein-coupled receptor kinase 2-like
	Modification date	20200313	20200313
	UniProtAcc	.	P32298 Main function of 5'-partner protein: FUNCTION: Specifically phosphorylates the activated forms of G protein-coupled receptors. GRK4-alpha can phosphorylate rhodopsin and its activity is inhibited by calmodulin; the other three isoforms do not phosphorylate rhodopsin and do not interact with calmodulin. GRK4-alpha and GRK4-gamma phosphorylate DRD3. Phosphorylates ADRB2. {ECO:0000269\|PubMed:19520868, ECO:0000269\|PubMed:8626439}.
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000537411, ENST00000274192, ENST00000538824, ENST00000504286,	ENST00000345167, ENST00000398051, ENST00000398052, ENST00000504933, ENST00000442472, ENST00000503518, ENST00000509545,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	6 X 2 X 5=60	7 X 7 X 4=196
	# samples	6	7
	** MAII score	log2(6/60*10)=0	log2(7/196*10)=-1.48542682717024 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Fusion gene context	PubMed: SRD5A1 [Title/Abstract] AND GRK4 [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: SRD5A1 [Title/Abstract] AND GRK4 [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	SRD5A1(6663079)-GRK4(3024140), # samples:2
Anticipated loss of major functional domain due to fusion event.	SRD5A1-GRK4 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. SRD5A1-GRK4 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. SRD5A1-GRK4 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. SRD5A1-GRK4 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Tgene	GRK4	GO:0031623	receptor internalization	20074556

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr5:6663079/chr4:3024140)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across SRD5A1 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across GRK4 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	Seq length (transcript)	BP loci (transcript)	Predicted start (transcript)	Predicted stop (transcript)	Seq length (amino acids)
ENST00000274192	SRD5A1	chr5	6663079	+	ENST00000398051	GRK4	chr4	3024140	+	1716	947	159	1613	484
ENST00000274192	SRD5A1	chr5	6663079	+	ENST00000398052	GRK4	chr4	3024140	+	1874	947	159	1751	530
ENST00000274192	SRD5A1	chr5	6663079	+	ENST00000504933	GRK4	chr4	3024140	+	1736	947	159	1613	484
ENST00000274192	SRD5A1	chr5	6663079	+	ENST00000345167	GRK4	chr4	3024140	+	1874	947	159	1751	530
ENST00000538824	SRD5A1	chr5	6663079	+	ENST00000398051	GRK4	chr4	3024140	+	1424	655	83	1321	412
ENST00000538824	SRD5A1	chr5	6663079	+	ENST00000398052	GRK4	chr4	3024140	+	1582	655	83	1459	458
ENST00000538824	SRD5A1	chr5	6663079	+	ENST00000504933	GRK4	chr4	3024140	+	1444	655	83	1321	412
ENST00000538824	SRD5A1	chr5	6663079	+	ENST00000345167	GRK4	chr4	3024140	+	1582	655	83	1459	458

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000274192	ENST00000398051	SRD5A1	chr5	6663079	+	GRK4	chr4	3024140	+	0.005917531	0.9940825
ENST00000274192	ENST00000398052	SRD5A1	chr5	6663079	+	GRK4	chr4	3024140	+	0.004424323	0.99557567
ENST00000274192	ENST00000504933	SRD5A1	chr5	6663079	+	GRK4	chr4	3024140	+	0.005461178	0.99453884
ENST00000274192	ENST00000345167	SRD5A1	chr5	6663079	+	GRK4	chr4	3024140	+	0.004424323	0.99557567
ENST00000538824	ENST00000398051	SRD5A1	chr5	6663079	+	GRK4	chr4	3024140	+	0.060800068	0.9391999
ENST00000538824	ENST00000398052	SRD5A1	chr5	6663079	+	GRK4	chr4	3024140	+	0.034946576	0.9650534
ENST00000538824	ENST00000504933	SRD5A1	chr5	6663079	+	GRK4	chr4	3024140	+	0.058776576	0.94122344
ENST00000538824	ENST00000345167	SRD5A1	chr5	6663079	+	GRK4	chr4	3024140	+	0.034946576	0.9650534

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for SRD5A1-GRK4

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Length(fusion protein)	BP in fusion protein	Peptide
SRD5A1	chr5	6663079	GRK4	chr4	3024140	655	191	FCFLSGRAKEHHEDLKPENILLDDRG
SRD5A1	chr5	6663079	GRK4	chr4	3024140	947	263	FCFLSGRAKEHHEDLKPENILLDDRG

Top

Potential FusionNeoAntigen Information of SRD5A1-GRK4 in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

SRD5A1-GRK4_6663079_3024140.msa

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA I	FusionNeoAntigen peptide	Binding score	Immunogenic score	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-B45:01	KEHHEDLKP	0.985	0.6486	8	17
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-B08:01	RAKEHHEDL	0.7505	0.5683	6	15
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-B41:01	HEDLKPENI	0.605	0.8628	11	20
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-B39:13	HEDLKPENI	0.5439	0.9378	11	20
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-B41:01	KEHHEDLKP	0.4064	0.6836	8	17
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-B50:01	KEHHEDLKP	0.1811	0.5188	8	17
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-A30:08	RAKEHHEDLK	0.9918	0.8044	6	16
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-B39:01	HHEDLKPENI	0.9894	0.9039	10	20
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-B38:01	HHEDLKPENI	0.986	0.9748	10	20
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-B38:02	HHEDLKPENI	0.9857	0.9746	10	20
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-B39:13	HEDLKPENIL	0.8879	0.8674	11	21
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-B39:01	HHEDLKPENIL	0.9997	0.8537	10	21
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-B38:02	HHEDLKPENIL	0.9994	0.951	10	21
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-B38:01	HHEDLKPENIL	0.9993	0.9518	10	21
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-B15:10	HHEDLKPENIL	0.9991	0.576	10	21
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-B38:01	EHHEDLKPENI	0.998	0.8622	9	20
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-B15:37	HHEDLKPENIL	0.9931	0.5739	10	21
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-B39:13	HEDLKPENILL	0.9903	0.872	11	22
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-C15:06	RAKEHHEDL	0.9846	0.9621	6	15
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-C03:08	RAKEHHEDL	0.973	0.9551	6	15
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-C03:19	RAKEHHEDL	0.9439	0.9917	6	15
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-C12:12	RAKEHHEDL	0.9372	0.936	6	15
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-B42:02	RAKEHHEDL	0.9064	0.5621	6	15
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-C06:03	RAKEHHEDL	0.9055	0.9908	6	15
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-C12:04	RAKEHHEDL	0.8849	0.9903	6	15
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-C02:06	RAKEHHEDL	0.7579	0.9669	6	15
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-B39:08	HEDLKPENI	0.6369	0.8779	11	20
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-B39:05	HHEDLKPENI	0.9838	0.8953	10	20
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-B39:08	HEDLKPENIL	0.9495	0.8359	11	21
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-B39:12	HHEDLKPENIL	0.9997	0.8635	10	21
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-B39:09	HHEDLKPENIL	0.9997	0.5099	10	21
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-B39:05	HHEDLKPENIL	0.9992	0.8539	10	21
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-B39:08	HEDLKPENILL	0.9964	0.831	11	22
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-B40:04	HEDLKPENI	0.9976	0.6365	11	20
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-C03:05	RAKEHHEDL	0.9387	0.957	6	15
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-C03:17	RAKEHHEDL	0.9281	0.9815	6	15
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-C03:03	RAKEHHEDL	0.9242	0.9909	6	15
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-C03:04	RAKEHHEDL	0.9242	0.9909	6	15
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-C16:04	RAKEHHEDL	0.8829	0.9668	6	15
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-C03:67	RAKEHHEDL	0.8816	0.9863	6	15
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-C12:03	RAKEHHEDL	0.8592	0.9743	6	15
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-C07:04	RAKEHHEDL	0.8335	0.9177	6	15
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-B07:13	RAKEHHEDL	0.8072	0.8835	6	15
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-B41:03	HEDLKPENI	0.7566	0.5508	11	20
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-B08:18	RAKEHHEDL	0.7505	0.5683	6	15
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-B08:12	RAKEHHEDL	0.7267	0.6633	6	15
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-C12:02	RAKEHHEDL	0.6939	0.9584	6	15
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-B39:11	HEDLKPENI	0.6302	0.8062	11	20
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-C16:02	RAKEHHEDL	0.6012	0.9917	6	15
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-C16:01	RAKEHHEDL	0.5503	0.9762	6	15
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-B39:02	HEDLKPENI	0.5327	0.9381	11	20
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-B50:04	KEHHEDLKP	0.1811	0.5188	8	17
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-B50:05	KEHHEDLKP	0.1811	0.5188	8	17
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-A30:01	RAKEHHEDLK	0.9923	0.8688	6	16
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-B38:05	HHEDLKPENI	0.986	0.9748	10	20
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-B39:11	HEDLKPENIL	0.9587	0.7699	11	21
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-B39:02	HEDLKPENIL	0.9212	0.8628	11	21
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-B39:11	HHEDLKPENI	0.9074	0.8353	10	20
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-B39:31	HHEDLKPENIL	0.9997	0.8552	10	21
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-B38:05	HHEDLKPENIL	0.9993	0.9518	10	21
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-B38:05	EHHEDLKPENI	0.998	0.8622	9	20
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-B15:09	HHEDLKPENIL	0.9978	0.608	10	21
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-B39:11	HEDLKPENILL	0.9965	0.7673	11	22
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-B39:11	HHEDLKPENIL	0.9964	0.8004	10	21
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	HLA-B39:02	HEDLKPENILL	0.9938	0.8679	11	22

Top

Potential FusionNeoAntigen Information of SRD5A1-GRK4 in HLA II

SRD5A1-GRK4_6663079_3024140.msa

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA II	FusionNeoAntigen peptide	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	DRB1-0467	HEDLKPENILLDDRG	11	26
SRD5A1-GRK4	chr5	6663079	chr4	3024140	947	DRB1-0467	HHEDLKPENILLDDR	10	25

Top

Fusion breakpoint peptide structures of SRD5A1-GRK4

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
7687	RAKEHHEDLKPENI	SRD5A1	GRK4	chr5	6663079	chr4	3024140	947

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of SRD5A1-GRK4

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele	PDB ID	File name	BPseq	Docking score	Glide score
HLA-B14:02	3BVN	7687	RAKEHHEDLKPENI	-6.07233	-6.07953
HLA-B52:01	3W39	7687	RAKEHHEDLKPENI	-5.45645	-5.46365
HLA-A24:02	5HGA	7687	RAKEHHEDLKPENI	-3.85827	-3.86547
HLA-B44:05	3DX8	7687	RAKEHHEDLKPENI	-4.76301	-4.77021

Top

Vaccine Design for the FusionNeoAntigens of SRD5A1-GRK4

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide sequence	FusionNeoAntigen RNA sequence
SRD5A1-GRK4	chr5	6663079	chr4	3024140	10	20	HHEDLKPENI	GCATCATGAAGACTTGAAGCCTGAGAATAT
SRD5A1-GRK4	chr5	6663079	chr4	3024140	10	21	HHEDLKPENIL	GCATCATGAAGACTTGAAGCCTGAGAATATTCT
SRD5A1-GRK4	chr5	6663079	chr4	3024140	11	20	HEDLKPENI	TCATGAAGACTTGAAGCCTGAGAATAT
SRD5A1-GRK4	chr5	6663079	chr4	3024140	11	21	HEDLKPENIL	TCATGAAGACTTGAAGCCTGAGAATATTCT
SRD5A1-GRK4	chr5	6663079	chr4	3024140	11	22	HEDLKPENILL	TCATGAAGACTTGAAGCCTGAGAATATTCTCCT
SRD5A1-GRK4	chr5	6663079	chr4	3024140	6	15	RAKEHHEDL	TAGAGCAAAAGAGCATCATGAAGACTT
SRD5A1-GRK4	chr5	6663079	chr4	3024140	6	16	RAKEHHEDLK	TAGAGCAAAAGAGCATCATGAAGACTTGAA
SRD5A1-GRK4	chr5	6663079	chr4	3024140	8	17	KEHHEDLKP	AAAAGAGCATCATGAAGACTTGAAGCC
SRD5A1-GRK4	chr5	6663079	chr4	3024140	9	20	EHHEDLKPENI	AGAGCATCATGAAGACTTGAAGCCTGAGAATAT

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide	FusionNEoAntigen RNA sequence
SRD5A1-GRK4	chr5	6663079	chr4	3024140	10	25	HHEDLKPENILLDDR	GCATCATGAAGACTTGAAGCCTGAGAATATTCTCCTTGATGATCG
SRD5A1-GRK4	chr5	6663079	chr4	3024140	11	26	HEDLKPENILLDDRG	TCATGAAGACTTGAAGCCTGAGAATATTCTCCTTGATGATCGTGG

Top

Information of the samples that have these potential fusion neoantigens of SRD5A1-GRK4

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type	Fusion gene	Hchr	Hbp	Henst	Tchr	Tbp	Tenst	Sample
ESCA	SRD5A1-GRK4	chr5	6663079	ENST00000274192	chr4	3024140	ENST00000345167	TCGA-L5-A8NW

Top

Potential target of CAR-T therapy development for SRD5A1-GRK4

Predicted 3D structure. We used RoseTTAFold.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Hgene

SRD5A1

chr5:6663079

chr4:3024140

ENST00000274192

111_131

237

260.0

Transmembrane

Helical

Hgene

SRD5A1

chr5:6663079

chr4:3024140

ENST00000274192

12_29

237

260.0

Transmembrane

Helical

Hgene

SRD5A1

chr5:6663079

chr4:3024140

ENST00000274192

151_171

237

260.0

Transmembrane

Helical

Hgene

SRD5A1

chr5:6663079

chr4:3024140

ENST00000274192

209_229

237

260.0

Transmembrane

Helical

Hgene

SRD5A1

chr5:6663079

chr4:3024140

ENST00000274192

86_106

237

260.0

Transmembrane

Helical

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene

Hchr

Hbp

Henst

Tgene

Tchr

Tbp

Tenst

DeepLoc result

Top

Related Drugs to SRD5A1-GRK4

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to SRD5A1-GRK4

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)